Sarepta Therapeutics (LTS:0L35) Treasury Stock: $-25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
62 GF Score
Price $16.28
GF Value $125.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Treasury Stock?

Sarepta Therapeutics LTS:0L35 +5.78% 62 Treasury Stock is $-25 Mil as of Mar. 2026. GuruFocus rates LTS:0L35 with a GF Score™ of 62/100 and a GF Value™ of $125.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Sarepta Therapeutics's treasury stock for the quarter that ended in Mar. 2026 was $-25 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Sarepta Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Treasury Stock Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -25.26

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -25.26 -25.26 -25.26 -25.26
LTS:0L35
62GF Score
Sarepta Therapeutics Inc LTS:0L35
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $-25 Mil mean?
Sarepta Therapeutics (LTS:0L35) has a Treasury Stock of $-25 Mil as of Mar. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Treasury Stock too high?
Sarepta Therapeutics' current Treasury Stock is $-25 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Treasury Stock compare to MPLT and ZYME?
Sarepta Therapeutics' Treasury Stock of $-25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Treasury Stock is $-25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $125.20, compared to a current price of $16.28 — trading 87% below its estimated fair value. The current Treasury Stock is $-25 Mil. Sarepta Therapeutics' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Treasury Stock is $-25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $16.28 is trading 87% below its estimated GF Value™ of $125.20. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • Treasury Stock: $-25 Mil
  • GF Value™: $125.20 vs. price of $16.28 (87% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
62GF Score

Get the complete analysis for LTS:0L35

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.28
Price
$125.20
GF Value